ENZ 📈 Enzo Biochem - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2941001024
ENZ: Proteins, Antibodies, Peptides, Small Molecules, Reagents, Kits
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York. Web URL: https://www.enzo.com
Additional Sources for ENZ Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ENZ Stock Overview
Market Cap in USD | 56m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1980-06-12 |
ENZ Stock Ratings
Growth 5y | -83.3% |
Fundamental | -45.2% |
Dividend | 44.4% |
Rel. Strength Industry | -907 |
Analysts | - |
Fair Price Momentum | 0.67 USD |
Fair Price DCF | - |
ENZ Dividends
Dividend Yield 12m | 13.16% |
Yield on Cost 5y | 4.17% |
Annual Growth 5y | % |
Payout Consistency | 100.0% |
ENZ Growth Ratios
Growth Correlation 3m | -10.1% |
Growth Correlation 12m | -57.9% |
Growth Correlation 5y | -71.8% |
CAGR 5y | -20.44% |
CAGR/Mean DD 5y | -0.46 |
Sharpe Ratio 12m | -0.93 |
Alpha | -56.22 |
Beta | 0.53 |
Volatility | 172.09% |
Current Volume | 450.6k |
Average Volume 20d | 235k |
What is the price of ENZ stocks?
As of December 21, 2024, the stock is trading at USD 0.76 with a total of 450,647 shares traded.
Over the past week, the price has changed by -25.23%, over one month by -22.73%, over three months by -29.15% and over the past year by -41.54%.
As of December 21, 2024, the stock is trading at USD 0.76 with a total of 450,647 shares traded.
Over the past week, the price has changed by -25.23%, over one month by -22.73%, over three months by -29.15% and over the past year by -41.54%.
Is Enzo Biochem a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Enzo Biochem (NYSE:ENZ) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -45.23 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENZ as of December 2024 is 0.67. This means that ENZ is currently overvalued and has a potential downside of -11.84%.
Probably not. Based on ValueRay Fundamental Analyses, Enzo Biochem (NYSE:ENZ) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -45.23 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENZ as of December 2024 is 0.67. This means that ENZ is currently overvalued and has a potential downside of -11.84%.
Is ENZ a buy, sell or hold?
Enzo Biochem has no consensus analysts rating.
Enzo Biochem has no consensus analysts rating.
What are the forecast for ENZ stock price target?
According to ValueRays Forecast Model, ENZ Enzo Biochem will be worth about 0.7 in December 2025. The stock is currently trading at 0.76. This means that the stock has a potential downside of -3.95%.
According to ValueRays Forecast Model, ENZ Enzo Biochem will be worth about 0.7 in December 2025. The stock is currently trading at 0.76. This means that the stock has a potential downside of -3.95%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 5.5 | 623.7% |
Analysts Target Price | 5.5 | 623.7% |
ValueRay Target Price | 0.7 | -3.9% |